+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
iPSC Cell Therapies Market - Global Forecast 2026-2032- Product Image
iPSC Cell Therapies Market - Global Forecast 2026-2032- Product Image
New

iPSC Cell Therapies Market - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6277894
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

iPSC Cell Therapies: Executive Overview

Induced pluripotent stem cell (iPSC) therapies reprogram mature cells into a pluripotent state, enabling the development of differentiated cells for research, disease modeling, drug discovery, and regenerative medicine. The field is progressing through advances in reprogramming, cell differentiation, genome editing, manufacturing, and quality control. Clinical translation remains dependent on demonstrating safety, functional consistency, durability, and practical delivery in humans.

Platform Advances Are Reshaping iPSC Therapy Development

The landscape is shifting from proof-of-concept biology toward reproducible, clinically deployable platforms. Key changes include improved differentiation protocols, more standardized cell banks, enhanced genomic characterization, automation, and closed-system manufacturing. Developers are also placing greater emphasis on immune compatibility, tumorigenicity controls, potency assays, cryopreservation, and scalable workflows. Regulatory expectations are increasingly focused on traceability, product consistency, long-term monitoring, and risk management across the full manufacturing process.

Artificial Intelligence Accelerates Design, Selection, and Quality Control

Artificial intelligence is contributing to iPSC research by analyzing high-dimensional genomic, transcriptomic, imaging, and phenotypic datasets. Machine-learning methods can support donor and clone selection, identify differentiation markers, optimize culture conditions, detect abnormal morphology, and prioritize therapeutic targets. AI may also improve process monitoring and release testing when models are trained on well-curated, representative datasets. Its value depends on transparent validation, protection against dataset bias, interpretable decision criteria, and continued human oversight in regulated development.

Regional Insights: Capacity and Regulation Shape Adoption

North America combines substantial biomedical research capacity with active translational and regulatory ecosystems. Europe benefits from coordinated scientific networks and established advanced-therapy frameworks, while Asia-Pacific is supported by strong capabilities in cell biology, manufacturing, and translational research across several economies. Latin America is developing expertise through academic and clinical partnerships, although infrastructure and funding vary. The Middle East is investing in life-science capacity and specialized healthcare, while Africa’s progress is linked to research partnerships, workforce development, and access to specialized facilities. Across all regions, harmonized standards, skilled personnel, and dependable manufacturing infrastructure remain decisive.

Group Insights: Strategic Blocs Influence Standards and Collaboration

The European Union provides a coordinated policy and research environment for advanced therapies, although implementation can differ among member states. The G7 supports high-level biomedical collaboration, research governance, and discussion of health-security priorities. BRICS countries bring diverse scientific, manufacturing, and healthcare capabilities, with collaboration shaped by national regulatory systems and infrastructure. ASEAN’s varied development levels create opportunities for regional knowledge sharing and clinical coordination. GCC states are strengthening specialized healthcare and biotechnology capabilities, while NATO members contribute to research networks, preparedness discussions, and technology cooperation that can indirectly support advanced cell-therapy development.

Country Insights: National Strengths Create Complementary Opportunities

The United States and Canada offer strong research, clinical, and biomanufacturing ecosystems. The United Kingdom, Germany, France, Italy, and Spain contribute established biomedical institutions and advanced-therapy expertise within broader European frameworks. Japan and South Korea have notable capabilities in regenerative medicine, cell manufacturing, and translational research, while China is advancing research infrastructure, clinical development, and industrial capacity. Australia combines strong biomedical research with specialized clinical programs. India is expanding its biotechnology base and scientific workforce. Brazil and Mexico are building regional capabilities, and Russia retains research capacity while operating within distinct institutional and regulatory conditions. In every country, progress depends on validated manufacturing, clear clinical pathways, and sustained specialist training.

Leadership Priorities for Safe and Scalable iPSC Translation

Industry leaders should establish end-to-end quality systems covering donor materials, reprogramming, cell banking, differentiation, formulation, storage, and administration. They should define clinically meaningful potency measures early, use orthogonal assays to detect genomic and phenotypic abnormalities, and build manufacturing strategies that can support consistent batches without compromising product characterization. Partnerships with hospitals, regulators, technology providers, and academic centers can improve trial design and implementation. Leaders should also create governance for AI-enabled decisions, invest in workforce development, plan long-term patient follow-up, and prioritize indications where the therapeutic mechanism and delivery route are clearly supported by evidence.

Research Methodology: Evidence-Based Assessment of the iPSC Therapy Landscape

This executive summary uses a structured review of the iPSC cell-therapy landscape, emphasizing peer-reviewed research, clinical and regulatory materials, manufacturing practices, and publicly documented scientific developments. Findings are organized across technology, translational, regional, group, and country dimensions. The assessment distinguishes established capabilities from emerging activity and avoids unsupported claims about commercial performance. Interpretation focuses on reproducibility, safety, regulatory readiness, infrastructure, collaboration, and the practical requirements for clinical adoption.

Conclusion: Translation Depends on Evidence, Control, and Collaboration

iPSC cell therapies are moving toward more disciplined translational development as biological engineering, manufacturing science, analytics, and regulatory practice mature. The principal opportunity is to convert flexible cellular platforms into consistent, safe, and clinically meaningful products. Progress will depend less on biological promise alone than on robust quality systems, validated potency and safety testing, scalable production, responsible AI use, and coordinated international collaboration. Organizations that align scientific innovation with operational and regulatory rigor will be best positioned to advance the field responsibly.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. iPSC Cell Therapies Market, by Indication
7.1. Introduction
7.2. Age-Related Macular Degeneration
7.2.1. Geographic Atrophy
7.2.2. Neovascular Age-Related Macular Degeneration
7.3. Cardiac Repair
7.4. Corneal Disorders
7.5. Metabolic Disease
7.6. Musculoskeletal Repair
7.7. Parkinsons Disease
7.8. Retinal Dystrophies
8. iPSC Cell Therapies Market, by Therapy Model
8.1. Introduction
8.2. Allogeneic
8.3. Autologous
9. iPSC Cell Therapies Market, by Cell Type
9.1. Introduction
9.2. Cardiomyocytes
9.3. Chondrocytes
9.4. Dopaminergic Neurons
9.5. Hepatocytes
9.6. Pancreatic Beta Cells
9.7. Retinal Pigment Epithelium
9.7.1. Monolayer RPE
9.7.2. Suspension RPE
10. iPSC Cell Therapies Market, by Stage Of Development
10.1. Introduction
10.2. Commercial
10.3. Early Stage Clinical
10.4. Late Stage Clinical
10.5. Preclinical
10.6. Research Use Only
11. iPSC Cell Therapies Market, by Product Type
11.1. Introduction
11.2. Adjunctive Products
11.3. Cell Banks And Cell Lines
11.4. Off The Shelf Therapeutics
11.5. Personalized Therapies
12. iPSC Cell Therapies Market, by End User
12.1. Introduction
12.2. Academic Research Institutes
12.3. Contract Developers And Biotech Partners
12.4. Hospitals And Clinics
12.5. Outpatient Clinics
12.6. Specialized Regenerative Centers
13. iPSC Cell Therapies Market, by Manufacturing Model
13.1. Introduction
13.2. Contract Manufacturing Organizations
13.2.1. Large Scale Bioreactor Services
13.2.2. Small Scale GMP Suites
13.3. Hybrid Models
13.4. In House Manufacturing
14. iPSC Cell Therapies Market, by Delivery Format
14.1. Introduction
14.2. Cryopreserved Frozen
14.3. Encapsulated Formulations
14.4. Fresh On Demand
14.5. Scaffold Based Implants
15. iPSC Cell Therapies Market, by Distribution Channel
15.1. Introduction
15.2. Direct To Provider
15.3. Distributor And Wholesaler
15.4. Hospital Based Cell Therapy Units
15.5. Specialty Pharmacy
16. iPSC Cell Therapies Market, by Region
16.1. Introduction
16.2. Asia-Pacific
16.3. North America
16.4. Latin America
16.5. Europe
16.6. Middle East
16.7. Africa
17. iPSC Cell Therapies Market, by Group
17.1. Introduction
17.2. ASEAN
17.3. GCC
17.4. European Union
17.5. BRICS
17.6. G7
17.7. NATO
18. iPSC Cell Therapies Market, by Country
18.1. Introduction
18.2. United States
18.3. Canada
18.4. Mexico
18.5. Brazil
18.6. United Kingdom
18.7. Germany
18.8. France
18.9. Russia
18.10. Italy
18.11. Spain
18.12. China
18.13. India
18.14. Japan
18.15. Australia
18.16. South Korea
19. Competitive Landscape
19.1. Market Share Analysis, 2025
19.2. Market Concentration Analysis, 2025
19.2.1. Concentration Ratio (CR)
19.2.2. Herfindahl Hirschman Index (HHI)
19.3. Recent Developments & Impact Analysis, 2025
19.4. Product Portfolio Analysis, 2025
19.5. Benchmarking Analysis, 2025
20. Company Profiles
20.1. Allele Biotechnology & Pharmaceuticals, Inc.
20.2. Aspen Neuroscience, Inc.
20.3. Avery Therapeutics, Inc.
20.4. BlueRock Therapeutics LP
20.5. Cellino Biotech, Inc.
20.6. Century Therapeutics
20.7. Cynata Therapeutics
20.8. Cytovia Therapeutics, Inc.
20.9. Eyestem Research
20.10. Fate Therapeutics
20.11. FUJIFILM Cellular Dynamics, Inc.
20.12. GC Therapeutics Inc.
20.13. Heartseed
20.14. iXCells Biotechnologies
20.15. Kenai Therapeutics Inc.
20.16. Kincell Bio
20.17. Laverock Therapeutics
20.18. LIfT BioSciences
20.19. Logomix Inc.
20.20. Mogrify Limited
20.21. Morphocell Technologies Inc.
20.22. Ncardia
20.23. Pluristyx Inc.
20.24. Reparon GmbH
20.25. Shinobi Therapeutics
20.26. Stem Pharm, Incorporated
20.27. Tenaya Therapeutics
20.28. Tolerance Bio
20.29. Trailhead Biosystems
20.30. TreeFrog Therapeutics
21. Key Experts
LIST OF FIGURES
FIGURE 1. Global iPSC Cell Therapies Market, Years Considered for the Study
FIGURE 2. Global iPSC Cell Therapies Market, Research Design
FIGURE 3. Global iPSC Cell Therapies Market, Research Framework
FIGURE 4. Global iPSC Cell Therapies Market, Data Triangulation
FIGURE 5. Global iPSC Cell Therapies Market Size, 2017-2032 (USD Million)
FIGURE 6. Global iPSC Cell Therapies Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global iPSC Cell Therapies Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global iPSC Cell Therapies Market Size, by Therapy Model, 2025 vs 2032 (%)
FIGURE 9. Global iPSC Cell Therapies Market Size, by Therapy Model, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global iPSC Cell Therapies Market Size, by Cell Type, 2025 vs 2032 (%)
FIGURE 11. Global iPSC Cell Therapies Market Size, by Cell Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global iPSC Cell Therapies Market Size, by Stage Of Development, 2025 vs 2032 (%)
FIGURE 13. Global iPSC Cell Therapies Market Size, by Stage Of Development, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global iPSC Cell Therapies Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 15. Global iPSC Cell Therapies Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global iPSC Cell Therapies Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global iPSC Cell Therapies Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global iPSC Cell Therapies Market Size, by Manufacturing Model, 2025 vs 2032 (%)
FIGURE 19. Global iPSC Cell Therapies Market Size, by Manufacturing Model, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global iPSC Cell Therapies Market Size, by Delivery Format, 2025 vs 2032 (%)
FIGURE 21. Global iPSC Cell Therapies Market Size, by Delivery Format, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global iPSC Cell Therapies Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 23. Global iPSC Cell Therapies Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 24. Global iPSC Cell Therapies Market Size, by Region, 2025 vs 2032 (%)
FIGURE 25. Global iPSC Cell Therapies Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 26. Global iPSC Cell Therapies Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 27. Global iPSC Cell Therapies Market Size, by Country, 2025 vs 2032 (%)
FIGURE 28. Global iPSC Cell Therapies Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 29. Global iPSC Cell Therapies Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global iPSC Cell Therapies Market Segmentation & Coverage
TABLE 2. Global iPSC Cell Therapies Market Size, 2017-2032 (USD Million)
TABLE 3. Global iPSC Cell Therapies Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Age-Related Macular Degeneration Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Age-Related Macular Degeneration Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Age-Related Macular Degeneration Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Geographic Atrophy Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Geographic Atrophy Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Geographic Atrophy Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Neovascular Age-Related Macular Degeneration Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Neovascular Age-Related Macular Degeneration Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Neovascular Age-Related Macular Degeneration Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Cardiac Repair Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Cardiac Repair Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Cardiac Repair Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Corneal Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Corneal Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Corneal Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Metabolic Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Metabolic Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Metabolic Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Musculoskeletal Repair Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Musculoskeletal Repair Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Musculoskeletal Repair Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Parkinsons Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Parkinsons Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Parkinsons Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Retinal Dystrophies Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Retinal Dystrophies Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Retinal Dystrophies Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global iPSC Cell Therapies Market Size, by Therapy Model, 2017-2032 (USD Million)
TABLE 32. Global Allogeneic Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Allogeneic Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Allogeneic Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Autologous Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Autologous Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Autologous Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global iPSC Cell Therapies Market Size, by Cell Type, 2017-2032 (USD Million)
TABLE 39. Global Cardiomyocytes Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Cardiomyocytes Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Cardiomyocytes Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Chondrocytes Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Chondrocytes Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Chondrocytes Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Dopaminergic Neurons Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Dopaminergic Neurons Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Dopaminergic Neurons Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Hepatocytes Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Hepatocytes Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Hepatocytes Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Pancreatic Beta Cells Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Pancreatic Beta Cells Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Pancreatic Beta Cells Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Retinal Pigment Epithelium Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Retinal Pigment Epithelium Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Retinal Pigment Epithelium Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Monolayer RPE Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Monolayer RPE Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Monolayer RPE Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Suspension RPE Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Suspension RPE Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Suspension RPE Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global iPSC Cell Therapies Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 64. Global Commercial Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Commercial Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Commercial Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Early Stage Clinical Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Early Stage Clinical Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Early Stage Clinical Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Late Stage Clinical Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Late Stage Clinical Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Late Stage Clinical Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Preclinical Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Preclinical Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Preclinical Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Research Use Only Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Research Use Only Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Research Use Only Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global iPSC Cell Therapies Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 80. Global Adjunctive Products Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Adjunctive Products Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Adjunctive Products Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Cell Banks And Cell Lines Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Cell Banks And Cell Lines Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Cell Banks And Cell Lines Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Off The Shelf Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Off The Shelf Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Off The Shelf Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Personalized Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Personalized Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Personalized Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global iPSC Cell Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 93. Global Academic Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global Academic Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global Academic Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Contract Developers And Biotech Partners Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Contract Developers And Biotech Partners Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Contract Developers And Biotech Partners Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global Hospitals And Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Global Hospitals And Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. Global Hospitals And Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 102. Global Outpatient Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Global Outpatient Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. Global Outpatient Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 105. Global Specialized Regenerative Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Global Specialized Regenerative Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. Global Specialized Regenerative Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 108. Global iPSC Cell Therapies Market Size, by Manufacturing Model, 2017-2032 (USD Million)
TABLE 109. Global Contract Manufacturing Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Global Contract Manufacturing Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. Global Contract Manufacturing Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 112. Global Large Scale Bioreactor Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Global Large Scale Bioreactor Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. Global Large Scale Bioreactor Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 115. Global Small Scale GMP Suites Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Global Small Scale GMP Suites Market Size, by Group, 2017-2032 (USD Million)
TABLE 117. Global Small Scale GMP Suites Market Size, by Country, 2017-2032 (USD Million)
TABLE 118. Global Hybrid Models Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. Global Hybrid Models Market Size, by Group, 2017-2032 (USD Million)
TABLE 120. Global Hybrid Models Market Size, by Country, 2017-2032 (USD Million)
TABLE 121. Global In House Manufacturing Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Global In House Manufacturing Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. Global In House Manufacturing Market Size, by Country, 2017-2032 (USD Million)
TABLE 124. Global iPSC Cell Therapies Market Size, by Delivery Format, 2017-2032 (USD Million)
TABLE 125. Global Cryopreserved Frozen Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Global Cryopreserved Frozen Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. Global Cryopreserved Frozen Market Size, by Country, 2017-2032 (USD Million)
TABLE 128. Global Encapsulated Formulations Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. Global Encapsulated Formulations Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. Global Encapsulated Formulations Market Size, by Country, 2017-2032 (USD Million)
TABLE 131. Global Fresh On Demand Market Size, by Region, 2017-2032 (USD Million)
TABLE 132. Global Fresh On Demand Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. Global Fresh On Demand Market Size, by Country, 2017-2032 (USD Million)
TABLE 134. Global Scaffold Based Implants Market Size, by Region, 2017-2032 (USD Million)
TABLE 135. Global Scaffold Based Implants Market Size, by Group, 2017-2032 (USD Million)
TABLE 136. Global Scaffold Based Implants Market Size, by Country, 2017-2032 (USD Million)
TABLE 137. Global iPSC Cell Therapies Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 138. Global Direct To Provider Market Size, by Region, 2017-2032 (USD Million)
TABLE 139. Global Direct To Provider Market Size, by Group, 2017-2032 (USD Million)
TABLE 140. Global Direct To Provider Market Size, by Country, 2017-2032 (USD Million)
TABLE 141. Global Distributor And Wholesaler Market Size, by Region, 2017-2032 (USD Million)
TABLE 142. Global Distributor And Wholesaler Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. Global Distributor And Wholesaler Market Size, by Country, 2017-2032 (USD Million)
TABLE 144. Global Hospital Based Cell Therapy Units Market Size, by Region, 2017-2032 (USD Million)
TABLE 145. Global Hospital Based Cell Therapy Units Market Size, by Group, 2017-2032 (USD Million)
TABLE 146. Global Hospital Based Cell Therapy Units Market Size, by Country, 2017-2032 (USD Million)
TABLE 147. Global Specialty Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 148. Global Specialty Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 149. Global Specialty Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 150. Global iPSC Cell Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 151. Asia-Pacific iPSC Cell Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 152. Asia-Pacific iPSC Cell Therapies Market Size, by Indication, 2017-2032 (USD Million)
TABLE 153. Asia-Pacific iPSC Cell Therapies Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 154. Asia-Pacific iPSC Cell Therapies Market Size, by Therapy Model, 2017-2032 (USD Million)
TABLE 155. Asia-Pacific iPSC Cell Therapies Market Size, by Cell Type, 2017-2032 (USD Million)
TABLE 156. Asia-Pacific iPSC Cell Therapies Market Size, by Retinal Pigment Epithelium, 2017-2032 (USD Million)
TABLE 157. Asia-Pacific iPSC Cell Therapies Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 158. Asia-Pacific iPSC Cell Therapies Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 159. Asia-Pacific iPSC Cell Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. Asia-Pacific iPSC Cell Therapies Market Size, by Manufacturing Model, 2017-2032 (USD Million)
TABLE 161. Asia-Pacific iPSC Cell Therapies Market Size, by Contract Manufacturing Organizations, 2017-2032 (USD Million)
TABLE 162. Asia-Pacific iPSC Cell Therapies Market Size, by Delivery Format, 2017-2032 (USD Million)
TABLE 163. Asia-Pacific iPSC Cell Therapies Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 164. North America iPSC Cell Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 165. North America iPSC Cell Therapies Market Size, by Indication, 2017-2032 (USD Million)
TABLE 166. North America iPSC Cell Therapies Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 167. North America iPSC Cell Therapies Market Size, by Therapy Model, 2017-2032 (USD Million)
TABLE 168. North America iPSC Cell Therapies Market Size, by Cell Type, 2017-2032 (USD Million)
TABLE 169. North America iPSC Cell Therapies Market Size, by Retinal Pigment Epithelium, 2017-2032 (USD Million)
TABLE 170. North America iPSC Cell Therapies Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 171. North America iPSC Cell Therapies Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 172. North America iPSC Cell Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 173. North America iPSC Cell Therapies Market Size, by Manufacturing Model, 2017-2032 (USD Million)
TABLE 174. North America iPSC Cell Therapies Market Size, by Contract Manufacturing Organizations, 2017-2032 (USD Million)
TABLE 175. North America iPSC Cell Therapies Market Size, by Delivery Format, 2017-2032 (USD Million)
TABLE 176. North America iPSC Cell Therapies Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 177. Latin America iPSC Cell Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 178. Latin America iPSC Cell Therapies Market Size, by Indication, 2017-2032 (USD Million)
TABLE 179. Latin America iPSC Cell Therapies Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 180. Latin America iPSC Cell Therapies Market Size, by Therapy Model, 2017-2032 (USD Million)
TABLE 181. Latin America iPSC Cell Therapies Market Size, by Cell Type, 2017-2032 (USD Million)
TABLE 182. Latin America iPSC Cell Therapies Market Size, by Retinal Pigment Epithelium, 2017-2032 (USD Million)
TABLE 183. Latin America iPSC Cell Therapies Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 184. Latin America iPSC Cell Therapies Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 185. Latin America iPSC Cell Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 186. Latin America iPSC Cell Therapies Market Size, by Manufacturing Model, 2017-2032 (USD Million)
TABLE 187. Latin America iPSC Cell Therapies Market Size, by Contract Manufacturing Organizations, 2017-2032 (USD Million)
TABLE 188. Latin America iPSC Cell Therapies Market Size, by Delivery Format, 2017-2032 (USD Million)
TABLE 189. Latin America iPSC Cell Therapies Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 190. Europe iPSC Cell Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 191. Europe iPSC Cell Therapies Market Size, by Indication, 2017-2032 (USD Million)
TABLE 192. Europe iPSC Cell Therapies Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 193. Europe iPSC Cell Therapies Market Size, by Therapy Model, 2017-2032 (USD Million)
TABLE 194. Europe iPSC Cell Therapies Market Size, by Cell Type, 2017-2032 (USD Million)
TABLE 195. Europe iPSC Cell Therapies Market Size, by Retinal Pigment Epithelium, 2017-2032 (USD Million)
TABLE 196. Europe iPSC Cell Therapies Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 197. Europe iPSC Cell Therapies Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 198. Europe iPSC Cell Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. Europe iPSC Cell Therapies Market Size, by Manufacturing Model, 2017-2032 (USD Million)
TABLE 200. Europe iPSC Cell Therapies Market Size, by Contract Manufacturing Organizations, 2017-2032 (USD Million)
TABLE 201. Europe iPSC Cell Therapies Market Size, by Delivery Format, 2017-2032 (USD Million)
TABLE 202. Europe iPSC Cell Therapies Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 203. Middle East iPSC Cell Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 204. Middle East iPSC Cell Therapies Market Size, by Indication, 2017-2032 (USD Million)
TABLE 205. Middle East iPSC Cell Therapies Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 206. Middle East iPSC Cell Therapies Market Size, by Therapy Model, 2017-2032 (USD Million)
TABLE 207. Middle East iPSC Cell Therapies Market Size, by Cell Type, 2017-2032 (USD Million)
TABLE 208. Middle East iPSC Cell Therapies Market Size, by Retinal Pigment Epithelium, 2017-2032 (USD Million)
TABLE 209. Middle East iPSC Cell Therapies Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 210. Middle East iPSC Cell Therapies Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 211. Middle East iPSC Cell Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 212. Middle East iPSC Cell Therapies Market Size, by Manufacturing Model, 2017-2032 (USD Million)
TABLE 213. Middle East iPSC Cell Therapies Market Size, by Contract Manufacturing Organizations, 2017-2032 (USD Million)
TABLE 214. Middle East iPSC Cell Therapies Market Size, by Delivery Format, 2017-2032 (USD Million)
TABLE 215. Middle East iPSC Cell Therapies Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 216. Africa iPSC Cell Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 217. Africa iPSC Cell Therapies Market Size, by Indication, 2017-2032 (USD Million)
TABLE 218. Africa iPSC Cell Therapies Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 219. Africa iPSC Cell Therapies Market Size, by Therapy Model, 2017-2032 (USD Million)
TABLE 220. Africa iPSC Cell Therapies Market Size, by Cell Type, 2017-2032 (USD Million)
TABLE 221. Africa iPSC Cell Therapies Market Size, by Retinal Pigment Epithelium, 2017-2032 (USD Million)
TABLE 222. Africa iPSC Cell Therapies Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 223. Africa iPSC Cell Therapies Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 224. Africa iPSC Cell Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 225. Africa iPSC Cell Therapies Market Size, by Manufacturing Model, 2017-2032 (USD Million)
TABLE 226. Africa iPSC Cell Therapies Market Size, by Contract Manufacturing Organizations, 2017-2032 (USD Million)
TABLE 227. Africa iPSC Cell Therapies Market Size, by Delivery Format, 2017-2032 (USD Million)
TABLE 228. Africa iPSC Cell Therapies Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 229. Global iPSC Cell Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 230. ASEAN iPSC Cell Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 231. ASEAN iPSC Cell Therapies Market Size, by Indication, 2017-2032 (USD Million)
TABLE 232. ASEAN iPSC Cell Therapies Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 233. ASEAN iPSC Cell Therapies Market Size, by Therapy Model, 2017-2032 (USD Million)
TABLE 234. ASEAN iPSC Cell Therapies Market Size, by Cell Type, 2017-2032 (USD Million)
TABLE 235. ASEAN iPSC Cell Therapies Market Size, by Retinal Pigment Epithelium, 2017-2032 (USD Million)
TABLE 236. ASEAN iPSC Cell Therapies Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 237. ASEAN iPSC Cell Therapies Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 238. ASEAN iPSC Cell Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 239. ASEAN iPSC Cell Therapies Market Size, by Manufacturing Model, 2017-2032 (USD Million)
TABLE 240. ASEAN iPSC Cell Therapies Market Size, by Contract Manufacturing Organizations, 2017-2032 (USD Million)
TABLE 241. ASEAN iPSC Cell Therapies Market Size, by Delivery Format, 2017-2032 (USD Million)
TABLE 242. ASEAN iPSC Cell Therapies Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 243. GCC iPSC Cell Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 244. GCC iPSC Cell Therapies Market Size, by Indication, 2017-2032 (USD Million)
TABLE 245. GCC iPSC Cell Therapies Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 246. GCC iPSC Cell Therapies Market Size, by Therapy Model, 2017-2032 (USD Million)
TABLE 247. GCC iPSC Cell Therapies Market Size, by Cell Type, 2017-2032 (USD Million)
TABLE 248. GCC iPSC Cell Therapies Market Size, by Retinal Pigment Epithelium, 2017-2032 (USD Million)
TABLE 249. GCC iPSC Cell Therapies Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 250. GCC iPSC Cell Therapies Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 251. GCC iPSC Cell Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 252. GCC iPSC Cell Therapies Market Size, by Manufacturing Model, 2017-2032 (USD Million)
TABLE 253. GCC iPSC Cell Therapies Market Size, by Contract Manufacturing Organizations, 2017-2032 (USD Million)
TABLE 254. GCC iPSC Cell Therapies Market Size, by Delivery Format, 2017-2032 (USD Million)
TABLE 255. GCC iPSC Cell Therapies Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 256. European Union iPSC Cell Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 257. European Union iPSC Cell Therapies Market Size, by Indication, 2017-2032 (USD Million)
TABLE 258. European Union iPSC Cell Therapies Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 259. European Union iPSC Cell Therapies Market Size, by Therapy Model, 2017-2032 (USD Million)
TABLE 260. European Union iPSC Cell Therapies Market Size, by Cell Type, 2017-2032 (USD Million)
TABLE 261. European Union iPSC Cell Therapies Market Size, by Retinal Pigment Epithelium, 2017-2032 (USD Million)
TABLE 262. European Union iPSC Cell Therapies Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 263. European Union iPSC Cell Therapies Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 264. European Union iPSC Cell Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 265. European Union iPSC Cell Therapies Market Size, by Manufacturing Model, 2017-2032 (USD Million)
TABLE 266. European Union iPSC Cell Therapies Market Size, by Contract Manufacturing Organizations, 2017-2032 (USD Million)
TABLE 267. European Union iPSC Cell Therapies Market Size, by Delivery Format, 2017-2032 (USD Million)
TABLE 268. European Union iPSC Cell Therapies Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 269. BRICS iPSC Cell Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 270. BRICS iPSC Cell Therapies Market Size, by Indication, 2017-2032 (USD Million)
TABLE 271. BRICS iPSC Cell Therapies Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 272. BRICS iPSC Cell Therapies Market Size, by Therapy Model, 2017-2032 (USD Million)
TABLE 273. BRICS iPSC Cell Therapies Market Size, by Cell Type, 2017-2032 (USD Million)
TABLE 274. BRICS iPSC Cell Therapies Market Size, by Retinal Pigment Epithelium, 2017-2032 (USD Million)
TABLE 275. BRICS iPSC Cell Therapies Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 276. BRICS iPSC Cell Therapies Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 277. BRICS iPSC Cell Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 278. BRICS iPSC Cell Therapies Market Size, by Manufacturing Model, 2017-2032 (USD Million)
TABLE 279. BRICS iPSC Cell Therapies Market Size, by Contract Manufacturing Organizations, 2017-2032 (USD Million)
TABLE 280. BRICS iPSC Cell Therapies Market Size, by Delivery Format, 2017-2032 (USD Million)
TABLE 281. BRICS iPSC Cell Therapies Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 282. G7 iPSC Cell Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 283. G7 iPSC Cell Therapies Market Size, by Indication, 2017-2032 (USD Million)
TABLE 284. G7 iPSC Cell Therapies Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 285. G7 iPSC Cell Therapies Market Size, by Therapy Model, 2017-2032 (USD Million)
TABLE 286. G7 iPSC Cell Therapies Market Size, by Cell Type, 2017-2032 (USD Million)
TABLE 287. G7 iPSC Cell Therapies Market Size, by Retinal Pigment Epithelium, 2017-2032 (USD Million)
TABLE 288. G7 iPSC Cell Therapies Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 289. G7 iPSC Cell Therapies Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 290. G7 iPSC Cell Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 291. G7 iPSC Cell Therapies Market Size, by Manufacturing Model, 2017-2032 (USD Million)
TABLE 292. G7 iPSC Cell Therapies Market Size, by Contract Manufacturing Organizations, 2017-2032 (USD Million)
TABLE 293. G7 iPSC Cell Therapies Market Size, by Delivery Format, 2017-2032 (USD Million)
TABLE 294. G7 iPSC Cell Therapies Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 295. NATO iPSC Cell Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 296. NATO iPSC Cell Therapies Market Size, by Indication, 2017-2032 (USD Million)
TABLE 297. NATO iPSC Cell Therapies Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 298. NATO iPSC Cell Therapies Market Size, by Therapy Model, 2017-2032 (USD Million)
TABLE 299. NATO iPSC Cell Therapies Market Size, by Cell Type, 2017-2032 (USD Million)
TABLE 300. NATO iPSC Cell Therapies Market Size, by Retinal Pigment Epithelium, 2017-2032 (USD Million)
TABLE 301. NATO iPSC Cell Therapies Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 302. NATO iPSC Cell Therapies Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 303. NATO iPSC Cell Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 304. NATO iPSC Cell Therapies Market Size, by Manufacturing Model, 2017-2032 (USD Million)
TABLE 305. NATO iPSC Cell Therapies Market Size, by Contract Manufacturing Organizations, 2017-2032 (USD Million)
TABLE 306. NATO iPSC Cell Therapies Market Size, by Delivery Format, 2017-2032 (USD Million)
TABLE 307. NATO iPSC Cell Therapies Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 308. Global iPSC Cell Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 309. United States iPSC Cell Therapies Market Size, 2017-2032 (USD Million)
TABLE 310. United States iPSC Cell Therapies Market Size, by Indication, 2017-2032 (USD Million)
TABLE 311. United States iPSC Cell Therapies Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 312. United States iPSC Cell Therapies Market Size, by Therapy Model, 2017-2032 (USD Million)
TABLE 313. United States iPSC Cell Therapies Market Size, by Cell Type, 2017-2032 (USD Million)
TABLE 314. United States iPSC Cell Therapies Market Size, by Retinal Pigment Epithelium, 2017-2032 (USD Million)
TABLE 315. United States iPSC Cell Therapies Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 316. United States iPSC Cell Therapies Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 317. United States iPSC Cell Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 318. United States iPSC Cell Therapies Market Size, by Manufacturing Model, 2017-2032 (USD Million)
TABLE 319. United States iPSC Cell Therapies Market Size, by Contract Manufacturing Organizations, 2017-2032 (USD Million)
TABLE 320. United States iPSC Cell Therapies Market Size, by Delivery Format, 2017-2032 (USD Million)
TABLE 321. United States iPSC Cell Therapies Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 322. Canada iPSC Cell Therapies Market Size, 2017-2032 (USD Million)
TABLE 323. Canada iPSC Cell Therapies Market Size, by Indication, 2017-2032 (USD Million)
TABLE 324. Canada iPSC Cell Therapies Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 325. Canada iPSC Cell Therapies Market Size, by Therapy Model, 2017-2032 (USD Million)
TABLE 326. Canada iPSC Cell Therapies Market Size, by Cell Type, 2017-2032 (USD Million)
TABLE 327. Canada iPSC Cell Therapies Market Size, by Retinal Pigment Epithelium, 2017-2032 (USD Million)
TABLE 328. Canada iPSC Cell Therapies Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 329. Canada iPSC Cell Therapies Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 330. Canada iPSC Cell Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 331. Canada iPSC Cell Therapies Market Size, by Manufacturing Model, 2017-2032 (USD Million)
TABLE 332. Canada iPSC Cell Therapies Market Size, by Contract Manufacturing Organizations, 2017-2032 (USD Million)
TABLE 333. Canada iPSC Cell Therapies Market Size, by Delivery Format, 2017-2032 (USD Million)
TABLE 334. Canada iPSC Cell Therapies Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 335. Mexico iPSC Cell Therapies Market Size, 2017-2032 (USD Million)
TABLE 336. Mexico iPSC Cell Therapies Market Size, by Indication, 2017-2032 (USD Million)
TABLE 337. Mexico iPSC Cell Therapies Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 338. Mexico iPSC Cell Therapies Market Size, by Therapy Model, 2017-2032 (USD Million)
TABLE 339. Mexico iPSC Cell Therapies Market Size, by Cell Type, 2017-2032 (USD Million)
TABLE 340. Mexico iPSC Cell Therapies Market Size, by Retinal Pigment Epithelium, 2017-2032 (USD Million)
TABLE 341. Mexico iPSC Cell Therapies Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 342. Mexico iPSC Cell Therapies Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 343. Mexico iPSC Cell Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 344. Mexico iPSC Cell Therapies Market Size, by Manufacturing Model, 2017-2032 (USD Million)
TABLE 345. Mexico iPSC Cell Therapies Market Size, by Contract Manufacturing Organizations, 2017-2032 (USD Million)
TABLE 346. Mexico iPSC Cell Therapies Market Size, by Delivery Format, 2017-2032 (USD Million)
TABLE 347. Mexico iPSC Cell Therapies Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 348. Brazil iPSC Cell Therapies Market Size, 2017-2032 (USD Million)
TABLE 349. Brazil iPSC Cell Therapies Market Size, by Indication, 2017-2032 (USD Million)

Companies Mentioned

  • Allele Biotechnology & Pharmaceuticals, Inc.
  • Aspen Neuroscience, Inc.
  • Avery Therapeutics, Inc.
  • BlueRock Therapeutics LP
  • Cellino Biotech, Inc.
  • Century Therapeutics
  • Cynata Therapeutics
  • Cytovia Therapeutics, Inc.
  • Eyestem Research
  • Fate Therapeutics
  • FUJIFILM Cellular Dynamics, Inc.
  • GC Therapeutics Inc.
  • Heartseed
  • iXCells Biotechnologies
  • Kenai Therapeutics Inc.
  • Kincell Bio
  • Laverock Therapeutics
  • LIfT BioSciences
  • Logomix Inc.
  • Mogrify Limited
  • Morphocell Technologies Inc.
  • Ncardia
  • Pluristyx Inc.
  • Reparon GmbH
  • Shinobi Therapeutics
  • Stem Pharm, Incorporated
  • Tenaya Therapeutics
  • Tolerance Bio
  • Trailhead Biosystems
  • TreeFrog Therapeutics

Related Topics

Related Reports

Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, & Forecasts, 2026 - Product Image

Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, & Forecasts, 2026

  • Report
  • 318 Pages
  • Global
From
iPSC Service Market - Global Forecast 2025-2030 - Product Image

iPSC Service Market - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Induced Pluripotent Stem Cell (iPSC) - Global Strategic Business Report - Product Image

Induced Pluripotent Stem Cell (iPSC) - Global Strategic Business Report

  • Report
  • 349 Pages
  • Global
From
Induced Pluripotent Stem Cell (iPSC) Market Report 2026 - Product Image

Induced Pluripotent Stem Cell (iPSC) Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Cell Therapy Manufacturing Market - Global Forecast 2026-2032 - Product Image

Cell Therapy Manufacturing Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.